Shuchi Nahar's Weekend Blog!

Syngene Q4FY21 and Full Year FY21 - Result Update  Twitter Handle: @shuchi_nahar Syngene International Limited on 28 th April 2021 announced its Q4FY21 and full-year results. The Company reported quarterly revenue from operations of Rs. 659 Cr and Rs. 2,184 Cr for the full year. Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year. Profit after tax (before exceptional gain) for the quarter increased by 15% year-on-year to Rs. 138 Cr, and by 4% to Rs. 382 Cr for the full year. Revenue Growth over the Years 1. Growth driven by an increase in sales from existing clients and acquisition of new clients  2. Engage, expand and extend the strategy to extend client relationship over a longer period of time  3. Growth in the total number of clients  4. Increase in average revenue from largest clients  5. Increase in number of services offered to clients The highlight...

  Syngene International Limited -  Company Overview Twitter Handle: @shuchi_nahar Link to FY 2020-21 Annual Report takeaways - https://myweekendspot.blogspot.com/2021/10/syngene-international-ltd-fy2020-21.html 1. Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agro-chemicals, etc. It currently caters to 293 global players including Bristol-Myers Squibb (BMS), Abbott, Baxter and Amgen, among others. SIL derives 95% of its revenues from exports. Mangalore API plant is constructed and validation is expected to be completed in FY21.  In FY20, Syngene extended its biologics discovery and preclinical research capabi...